RadNet, Inc. reports recurring developments in outpatient diagnostic imaging, digital health, and radiology technology. The company operates owned and managed imaging centers that provide MRI, CT, PET/CT, mammography, ultrasound, X-ray, fluoroscopy, nuclear medicine, and related procedures for physicians and patients across U.S. markets.
RadNet news commonly covers financial results, imaging-center procedure volumes, guidance updates, joint ventures, acquisitions, and customer or technology collaborations. Its Digital Health segment includes DeepHealth, which provides radiology information technology, AI-powered health informatics, clinical AI applications, patient engagement tools, operational AI, teleradiology services, and related products for the diagnostic imaging industry.
RadNet (RDNT) announced a collaboration with WIN-NextGen to introduce middle school students, high school students and young adults to medical imaging careers. The program covers students aged 12 to 17 throughout Maryland, Washington, D.C. and parts of Virginia, as well as young adults aged 18 to 24. Participants will have access to digital learning modules, mentorship and imaging center shadowing experiences.
RadNet expects the collaboration to expand over time to include internship and scholarship opportunities. An official launch event is planned for October 24, 2026, from 12:00 to 2:00 pm ET at Advanced Radiology Timonium Crossings Imaging Center in Timonium, Maryland. Students and their families will tour the facility, see demonstrations and participate in educational activities.
RadNet (RDNT) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026, at 7:45 a.m. Eastern Time.
The presentation will be given by Executive Vice President and Chief Financial Officer Mark Stolper. A simultaneous and archived webcast of RadNet’s presentation will be available online at the provided webcast link.
RadNet (RDNT) will host a free public prostate cancer webinar on Saturday, September 19, 2026, featuring clinical experts and a cancer survivor.
The online event, titled “Let’s Talk About It: Prostate Cancer: Your Questions Answered,” will cover prostate cancer risk factors, screening, diagnosis, treatment options and life after cancer. Panelists include a radiologist, a urologist and robotic surgeon, and a prostate cancer survivor who used RadNet’s Enhanced Prostate Screening, which combines prostate MRI with AI. The session will also address the role of prostate MRI in guiding targeted biopsies and include a live Q&A where attendees can submit questions.
RadNet (RDNT) will present at the Jefferies Healthcare Services Conference on September 15, 2026 at 9:10 a.m. Central Time in Nashville, Tennessee.
Executive Vice President and Chief Strategy Officer Dr. Greg Sorensen will deliver the presentation. Simultaneous and archived webcasts will be accessible via a dedicated event link and through RadNet's website under the “About RadNet” section and “News and Press Releases” sub-menu.
RadNet (NASDAQ: RDNT) reported second quarter 2026 results with record Total Company revenue of $622.7 million, up 25.0% year over year, and record Adjusted EBITDA(1) of $99.7 million, up 22.7%. Digital Health revenue (including intersegment) rose 56.5% to $32.4 million, while Annual Recurring Revenue(4) nearly doubled to $105.5 million versus June 30, 2025.
GAAP net income was $7.5 million (EPS $0.10), down from $14.5 million (EPS $0.19), impacted by items including R&D, intangibles amortization and acquisition costs. Adjusted Earnings(3) were $23.2 million (EPS $0.29) versus $25.7 million (EPS $0.34) a year ago. RadNet ended June 30, 2026 with $726.3 million of cash and a Net Debt to Adjusted EBITDA(1) Ratio(5) of 1.8x.
For the Imaging Center segment, Adjusted EBITDA(1) margin rose to 16.1% and advanced imaging reached 29.9% of procedural volumes. RadNet raised 2026 Imaging Center guidance for revenue, Adjusted EBITDA(1) and Free Cash Flow(2), while reaffirming all Digital Health guidance ranges.
RadNet (NASDAQ: RDNT) will host a conference call to discuss its second quarter 2026 financial results on Monday, August 10, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern). Investors can access the live call by phone or via a simultaneous webcast, with replay options available.
DeepHealth, a RadNet (NASDAQ: RDNT) subsidiary, received two FDA 510(k) clearances for its AI-powered Breast Suite: BAC Assessment and prior exam integration, branded Mammo Dx.
The tools add cardiovascular risk insights and automated prior-study comparison, targeting improved cancer detection, fewer recalls, and better-informed decisions.
RadNet (NASDAQ: RDNT) entered Incremental Amendment No. 3 to its first lien credit agreement, adding a $250 million incremental term loan maturing April 18, 2031 alongside the existing $958.7 million term loan.
Quarterly principal rises to about $3.1 million, while interest rates on the Term Loan and undrawn $282 million revolver are reduced by 0.25%. Proceeds are expected to fund acquisitions, organic growth, health system partnerships and other corporate purposes, adding to a $455 million cash balance as of March 31, 2026.
DeepHealth, a RadNet (NASDAQ: RDNT) subsidiary, launched Reporting Pro, an AI-powered radiology reporting platform now commercially available in the US and UK. The solution unifies speech recognition, clinical AI findings, measurements, AI-generated impressions, quality assurance and structured reporting into one workflow.
Reporting Pro integrates FDA-cleared and CE-marked AI tools, uses generative AI to draft impressions, and is designed to work with any PACS and RIS. It is being deployed across RadNet and with initial external customers, and supports all major imaging modalities.
RadNet (NASDAQ: RDNT) plans to secure a $200 million incremental term loan under an amendment to its First Lien Credit and Guaranty Agreement. The new loan would form part of its existing term loan and mature on April 18, 2031.
Proceeds are expected to support acquisitions, organic expansion, health system partnerships and general corporate purposes, giving RadNet added flexibility for strategic growth. Completion of the loan transaction is subject to customary market and other conditions.